New Results
The Powers and Perils of Post-Marketing Data Analysis: Quantification and Mitigation of Biases in the FDA Adverse Event Reporting System
Mateusz Maciejewski, Eugen Lounkine, Steven Whitebread, Pierre Farmer, Brian K. Shoichet, Laszlo Urban
doi: https://doi.org/10.1101/068692
Mateusz Maciejewski
1Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, USA.
PhDEugen Lounkine
2Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.
PhDSteven Whitebread
2Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.
BSPierre Farmer
3Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
PhDBrian K. Shoichet
4University of California, San Francisco, San Francisco, California 94158, USA.
PhDLaszlo Urban
2Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.
MD, PhDArticle usage
Posted August 10, 2016.
The Powers and Perils of Post-Marketing Data Analysis: Quantification and Mitigation of Biases in the FDA Adverse Event Reporting System
Mateusz Maciejewski, Eugen Lounkine, Steven Whitebread, Pierre Farmer, Brian K. Shoichet, Laszlo Urban
bioRxiv 068692; doi: https://doi.org/10.1101/068692
Subject Area
Subject Areas
- Biochemistry (11573)
- Bioengineering (8623)
- Bioinformatics (28874)
- Biophysics (14805)
- Cancer Biology (11944)
- Cell Biology (17170)
- Clinical Trials (138)
- Developmental Biology (9306)
- Ecology (14022)
- Epidemiology (2067)
- Evolutionary Biology (18129)
- Genetics (12148)
- Genomics (16619)
- Immunology (11709)
- Microbiology (27697)
- Molecular Biology (11392)
- Neuroscience (60106)
- Paleontology (447)
- Pathology (1849)
- Pharmacology and Toxicology (3184)
- Physiology (4878)
- Plant Biology (10279)
- Synthetic Biology (2849)
- Systems Biology (7291)
- Zoology (1619)